Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter

被引:120
作者
Wong, Vincent Wai-Sun [1 ,2 ]
Petta, Salvatore [3 ]
Hiriart, Jean-Baptiste [4 ]
Camma, Calogero [3 ]
Wong, Grace Lai-Hung [1 ,2 ]
Marra, Fabio [5 ]
Vergniol, Julien [4 ]
Chan, Anthony Wing-Hung [6 ]
Tuttolomondo, Antonino [7 ]
Merrouche, Wassil [4 ]
Chan, Henry Lik-Yuen [1 ,2 ]
Le Bail, Brigitte [8 ,9 ]
Arena, Umberto [5 ]
Craxi, Antonio [3 ]
de Ledinghen, Victor [4 ,8 ]
机构
[1] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, State Key Lab Digest Dis, Hong Kong, Hong Kong, Peoples R China
[3] Univ Palermo, Sez Gastroenterol, DiBiMIS, Palermo, Italy
[4] Bordeaux Univ Hosp, Ctr Invest Fibrose Hepat, Hop Haut Leveque, Pessac, France
[5] Univ Firenze, Dipartimento Med Sperimentale & Clin, Florence, Italy
[6] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China
[7] Univ Palermo, Sez Med Interna & Cardioangiol, DiBiMIS, Palermo, Italy
[8] Bordeaux Univ, INSERM U1053, Bordeaux, France
[9] Bordeaux Univ Hosp, Hop Pellegrin, Serv Pathol, Bordeaux, France
关键词
FibroScan; Liver stiffness measurement; Non-alcoholic fatty liver disease; Hepatic steatosis; Liver biopsy; Diagnostic accuracy; MAGNETIC-RESONANCE SPECTROSCOPY; CHRONIC HEPATITIS-B; TRANSIENT ELASTOGRAPHY; STIFFNESS MEASUREMENT; XL PROBE; HEPATOCELLULAR-CARCINOMA; NONALCOHOLIC STEATOHEPATITIS; NONINVASIVE ASSESSMENT; OBESE-PATIENTS; UNITED-STATES;
D O I
10.1016/j.jhep.2017.05.005
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Controlled attenuation parameter (CAP) can be performed together with liver stiffness measurement (LSM) by transient elastography (TE) and is often used to diagnose fatty liver. We aimed to define the validity criteria of CAP. Methods: CAP was measured by the M probe prior to liver biopsy in 754 consecutive patients with different liver diseases at three centers in Europe and Hong Kong (derivation cohort, n = 340; validation cohort, n = 414; 101 chronic hepatitis B, 154 chronic hepatitis C, 349 non-alcoholic fatty liver disease, 37 autoimmune hepatitis, 49 cholestatic liver disease, 64 others; 277 F3-4; age 52 +/- 14; body mass index 27.2 +/- 5.3 kg/m(2)). The primary outcome was the diagnosis of fatty liver, defined as steatosis involving >= 5% of hepatocytes. Results: The area under the receiver-operating characteristics curve (AUROC) for CAP diagnosis of fatty liver was 0.85 (95% CI 0.82-0.88). The interquartile range (IQR) of CAP had a negative correlation with CAP (r = -0.32, p < 0.001), suggesting the IQR-to-median ratio of CAP would be an inappropriate validity parameter. In the derivation cohort, the IQR of CAP was associated with the accuracy of CAP (AUROC 0.86, 0.89 and 0.76 in patients with IQR of CAP <20 [15% of patients], 20-39 [51%], and >= 40 dB/m [33%], respectively). Likewise, the AUROC of CAP in the validation cohort was 0.90 and 0.77 in patients with IQR of CAp <40 and >= 40 dB/m, respectively (p = 0.004). The accuracy of CAP in detecting grade 2 and 3 steatosis was lower among patients with body mass index >= 30 kg/m(2) and F3-4 fibrosis. Conclusions: The validity of CAP for the diagnosis of fatty liver is lower if the IQR of CAP is >= 40 dB/m. Lay summary: Controlled attenuation parameter (CAP) is measured by transient elastography (TE) for the detection of fatty liver. In this large study, using liver biopsy as a reference, we show that the variability of CAP measurements based on its interquartile range can reflect the accuracy of fatty liver diagnosis. In contrast, other clinical factors such as adiposity and liver enzyme levels do not affect the performance of CAP. (C) 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:577 / 584
页数:8
相关论文
共 50 条
  • [31] Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis
    Semmler, Georg
    Woeran, Katharina
    Scheiner, Bernhard
    Unger, Lukas Walter
    Paternostro, Rafael
    Stift, Judith
    Schwabl, Philipp
    Bucsics, Theresa
    Bauer, David
    Simbrunner, Benedikt
    Sfaettermayer, Albert Friedrich
    Pinter, Matthias
    Traunerl, Michael
    Reiberger, Thomas
    Mandorfer, Mattias
    [J]. UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2020, 8 (03) : 321 - 331
  • [32] Prevalence of fatty liver disease in patients with inflammatory bowel disease: a transient elastography study on the basis of a controlled attenuation parameter
    Kani, Haluk Tarik
    Deliktas, Ilknur
    Yilmaz, Yusuf
    [J]. MARMARA MEDICAL JOURNAL, 2019, 32 (02): : 68 - 70
  • [33] Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis
    Pu, Ke
    Wang, Yuping
    Bai, Suyang
    Wei, Hui
    Zhou, Yongning
    Fan, Jiangao
    Qiao, Liang
    [J]. BMC GASTROENTEROLOGY, 2019, 19 (1)
  • [34] Interobserver reproducibility of the controlled attenuation parameter (CAP) for quantifying liver steatosis
    Ferraioli, Giovanna
    Tinelli, Carmine
    Lissandrin, Raffaella
    Zicchetti, Mabel
    Rondanelli, Mariangela
    Perani, Guido
    Bernuzzi, Stefano
    Salvaneschi, Laura
    Filice, Carlo
    [J]. HEPATOLOGY INTERNATIONAL, 2014, 8 (04) : 576 - 581
  • [35] Defining values for controlled attenuation parameter and liver stiffness in youth without liver disease
    Ramirez-Velez, Robinson
    Garcia-Hermoso, Antonio
    Correa-Rodriguez, Maria
    Izquierdo, Mikel
    [J]. PEDIATRIC RESEARCH, 2022, 91 (04) : 912 - 920
  • [36] Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients
    Darweesh, Samar K.
    AbdElAziz, Rasha A.
    Abd-ElFatah, Dina S.
    AbdElazim, Naglaa A.
    Fathi, Shaimaa A.
    Attia, Dina
    AbdAllah, Mohammed
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2019, 31 (05) : 633 - 641
  • [37] Usefulness of liver test and controlled attenuation parameter in detection of nonalcoholic fatty liver disease in patients with chronic renal failure and coronary heart disease
    Mikolasevic, Ivana
    Orlic, Lidija
    Zaputovic, Luka
    Racki, Sanjin
    Cubranic, Zlatko
    Anic, Kata
    Devcic, Bosiljka
    Stimac, Davor
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2015, 127 (11-12) : 451 - 458
  • [38] Body mass index–based controlled attenuation parameter cut-offs for assessment of hepatic steatosis in non-alcoholic fatty liver disease
    Ramesh Shalimar
    Gyanranjan Kumar
    Rahul Rout
    Rajini Kumar
    Prasenjit Yadav
    Sandeep Das
    Deepak Aggarwal
    Anoop Gunjan
    Baibaswata Saraya
    [J]. Indian Journal of Gastroenterology, 2020, 39 : 32 - 41
  • [39] Controlled attenuation parameter and magnetic resonance spectroscopy-measured liver steatosis are discordant in obese HIV-infected adults
    Price, Jennifer C.
    Dodge, Jennifer L.
    Ma, Yifei
    Scherzer, Rebecca
    Korn, Natalie
    Tillinghast, Kyle
    Peters, Marion G.
    Noworolski, Susan
    Tien, Phyllis C.
    [J]. AIDS, 2017, 31 (15) : 2119 - 2125
  • [40] Low-dose attenuation correction in diagnosis of non-alcoholic fatty liver disease
    Ahmed, Amjad M.
    Ebid, Mohamed E.
    Ajlan, Amr M.
    Al-Mallah, Mouaz H.
    [J]. ABDOMINAL RADIOLOGY, 2017, 42 (10) : 2454 - 2459